​

AN2 Therapeutics Stock (NASDAQ:ANTX)

ForecastOwnershipFinancialsChart
AN2 Therapeutics by TradingView

Previous Close

$3.91

52W Range

$1.00 - $6.91

50D Avg

$4.10

200D Avg

$2.16

Market Cap

$115.09M

Avg Vol (3M)

$326.11K

Beta

-0.98

Div Yield

-

ANTX Company Profile

AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease. This enterprise was established in 2017 and operates from its headquarters situated in Menlo Park, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

22

IPO Date

Mar 25, 2022

Website

ANTX Performance

ANTX Financial Summary

Dec 25Dec 24Dec 23
Revenue---
Operating Income$-38.11M$-54.55M$-69.64M
Net Income$-35.17M$-51.32M$-64.73M
EBITDA$-38.11M$3.23M$4.90M
Basic EPS$-1.16$-1.72$-2.74
Diluted EPS$-1.16$-1.72$-2.74

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

TickerCompany
PLURPluri Inc.
INTSIntensity Therapeutics, Inc.
IBIOiBio, Inc.
NXTCNextCure, Inc.
QTTBQ32 Bio Inc.
VRCAVerrica Pharmaceuticals Inc.
SABSSAB Biotherapeutics, Inc.
BOLDBoundless Bio, Inc.
ITRMIterum Therapeutics plc
PSTVPlus Therapeutics, Inc.